You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • SAT0181 Low dose interleukin-2 combined with tocilizumab selectively increases regulatory t cells helping refractory rheumatoid arthritis patients achieve remission more rapidly

Citation Tools

Article menu

Download PDFPDF

Poster Presentations
Rheumatoid arthritis - other biologic treatment
SAT0181 Low dose interleukin-2 combined with tocilizumab selectively increases regulatory t cells helping refractory rheumatoid arthritis patients achieve remission more rapidly
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Sheng-Xiao Z, Xiao-Wen M, Xiao-Qing L, et al
SAT0181 Low dose interleukin-2 combined with tocilizumab selectively increases regulatory t cells helping refractory rheumatoid arthritis patients achieve remission more rapidly
Annals of the Rheumatic Diseases 2017;76:839.